Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea Drug Pricing Strategies Needed Now, Says Merck KGaA's South Korean President Juergen Koenig

This article was originally published in The Pink Sheet Daily

Executive Summary

To ramp up pharmaceutical sales, the company may have to overcome some considerable challenges directly linked to the country's increasingly indebted health care system.

You may also be interested in...



South Korea Health Ministry's New Pricing Policy Draws Ire From Local Generics Makers

SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs' new pricing policy, currently being re-crafted, is drawing criticism from the country's domestic generic drug makers because part of the new policy is calling for much lower prices on generics and original products coming off patent protection

Philippines Government Slaps Price Caps On Innovative Drugs; Pfizer Reacts With Disappointment

SHANGHAI - After pressuring international pharmaceutical companies to drastically reduce prices on a list of basic drugs, with mixed results, the Philippines government is imposing price caps by executive order in a move that will take effect August 15

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS068724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel